anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants are exposed to a Healthy Eating "Peaches!"- media campaign intervention comprising 3 phases: the media campaign, the medical chart reminder, and a combination of media campaign and chart reminder. Participants also undergo telephone interviews during years 2-4.
An apparatus (100), control system (150) and methods are provided for directly measuring a pressure gradient, i.e. by real-time pressure measurements, with particular application for in situ measurement of transvalvular blood pressure gradients for the aortic valve and other heart valves, using minimally-invasive techniques. The apparatus takes the form of a multi-sensor assembly, e.g. enclosed within a micro-catheter or a steerable guidewire, and comprises a plurality of optical pressure sensors (10) is arranged along a length of the distal end portion (101), for measuring pressure simultaneously at each sensor location. For example, four MOMS optical pressure sensors (10), and optionally, a flow sensor (20), are incorporated into a distal end portion (101) having a diameter of 0.89 mm or less, and preferably 0.46 mm or less. Beneficially, all sensors are optically coupled, via respective optical fibers (11), to an optical coupler (112) at the proximal end of the multi-sensor apparatus, without requiring electrical connections.
PURPOSE:To obtain the title compsn. which has a less skin irritating tendency, is excellent in lathering properties, and gives highly rich feeling in lather quality, by incorporating at least one alkyloylalkyltaurine salt anionic surfactant and at least one particular nonionic surfactant. CONSTITUTION:At least one alkyloylalkyltaurine salt anionic surfactant (A) of formula I (wherein R1 is a 7-19C alkyl, alkenyl or hydroxyalkyl; R2 is a 1-3C lower alkyl; and M is an alkali metal, an org. amine or the like) and at least one nonionic surfactant (B) composed of an alkyl glucoside of formula II (wherein a is 1-15; and n is 7-19) are incorporated as essential components in an A to B wt. ratio of 0.01-100 and in such an amt. that the sum of A+B is 2-50wt.% based on the total amt. of the compsn. According to necessity, 0.1-20wt.% amphoteric surfactant (C), such as sodium 2-undecyl-N,N, N-(hydroxyethylcarboxymethyl)-2-imidazolinate, and a higher alcohol, an oil component, a water-soluble polymer, a cationic polymer and other additives (D) are added thereto.
The invention discloses a traditional Chinese medicine pill for tonifying qi, strengthening spleen and eliminating stagnation, which is prepared from the following components in part by weight: 11 traditional Chinese medicines such as raw astragalus, codonopsis pilosula, fried bighead atractylodes rhizome, poria cocos, raw coix seed, dried orange peel, inula flower, white mustard seed, calcined concha arcae, thunberg fritillary bulb and oyster are combined in a formula. 1. Has no influence or little influence on normal physiological functions and no toxic or side effect. 2. The effect is nonspecific and broad-spectrum. 3. Has effects in regulating immunity, regulating yingfen and weifen disharmony, dispelling qi, resolving phlegm, and treating lung and spleen qi stagnation, turbid qi, and qi stagnation manifested as swelling and qi tumor. 4. Can effectively improve symptoms and physical signs of patients with spleen deficiency and lung qi stagnation, benefit qi and reduce phlegm, regulate qi and remove stagnation, soften hardness and dissipate stagnation, and strengthen body resistance to eliminate pathogenic factors.
A biguanide containing compound comprising one or more nitric oxide (NO) molecules bound thereto, wherein the biguanide is obtainable by reacting a precursor compound of Formula (I): With NO gas or a nitrosylating agent, wherein R1-12 are as defined herein. A preferred biguanide containing compound is Chlorhexidine. The NO-complexed compound may be incorporated into a porous framework material, such as a metal organic framework material (MOF), within the internal pores and/or channels of the MOF. A porous framework material or MOF comprising an extra-framework NO complexed compound is also discloses, wherein the NO complexed compound comprises one or more functional groups selected from the Formulae X, A, B C or D as described herein. Methods of preparing porous framework materials or MOFS comprising an extra-framework NO complexed compound are also provided. The NO complexed compounds and porous framweorks comprising the same are disclosed to have use as antibacterials in the treatment of infections.
The liquid interferon compositions have pH from 4.0 to 7.2. They include interferon-beta and a stabilizing agent from 0.3 to 5% of the weight which is an amino acid selected from the group including acidic amino acids, arginine and glycine. Optionally, in order to ensure sufficient ionic strength salt is being added. The liquid composition is not being freeze-dried or cavitated earlier. Preferably the liquid is kept in a vessel the contacting surface of which with the liquid is covered by a material which is inert to the adsorption of interferon-beta. The invention also relates to a mastic for parenteral introduction of liquid interferon composition and to a method for the stabilization of liquid interferon compositions. 43 claims
FIELD: medicine. SUBSTANCE: invention relates to etiotropic chemotherapy of viral infections, in part, agent used for inhibition of HIV and CMV infections and method of their inhibition. Method involves application of amino acid and dipeptide derivatives of fullerene of the general formula C 60 -X where C 60  means fullerene nucleus; X means NH-CHR-COOH, NH-(CH 2 ) n -COOH, NH-CHR-CO-NH-CHR-COOH where n = 2-6; R means by-side radical of natural amino acid or dipeptide as agent for inhibition of viral infections, in part, HIV and CMV infections. Method of application of water-soluble amino acid or dipeptide derivatives of fullerene of the general formula C 60' -X as agent for inhibition of viral infections involves its effect on infected cellular cultures in vitro with effective inhibitory dose. EFFECT: enhanced inhibitory activity of agent. 20 cl, 1 tbl
The aim of this study is to investigate the feasibility of an intervention to reduce sedentary behaviour in n=45 older adults undergoing orthopaedic surgery, at Russells Hall Hospital, Dudley, Birmingham, UK. Recruitment will be via screening of surgery lists followed by direct contact with potentially eligible participants. The intervention is designed utilising Self Determination Theory. It is designed to have multiple components: incorporating individualised feedback on sitting time, education about sedentary behaviour, individualised goal-setting and environmental modification according to each participant's own behavioural patterns and capabilities, motivational interviewing, and biweekly phone calls.

Due to variation in surgery times, the intervention will be variable but can last up to 18 weeks. Each participant will undertake 3-5 visits depending on whether they are in the control group (n=3 visits) or intervention group (n=5 visits). The intervention group will undergo baseline assessments, two intervention meetings, pre-surgical assessments, and a 6-week post-surgical follow up. These visits will occur in different weeks for each participant due to the variability of surgery, however visit 2 will occur 1 week after visit 1. Visit 3 will occur shortly thereafter but may also be combined with visit 2. Visit 4 will occur the week prior to surgery, which is intended to be 6-10 weeks after baseline. Visit 5 occurs 6 weeks post-surgery, which should be 12-18 weeks post-baseline. The primary outcome measure will be feasibility, assessed quantitatively with study statistics. Secondary outcome will be mixed-methods assessment of feasibility via bespoke participant questionnaires. Exploratory outcomes will cover a number of mental and physical health variables, including blood measures to assess cardiometabolic biomarkers, as well as physical function using the short physical performance battery (SPPB). Surgical recovery will be assessed using the Oxford Hip/Knee score and the SPPB. The results of this feasibility study will serve to aid the design of a definitive trial of an intervention to reduce sedentary behaviour in this population.
BACKGROUND: Laparoscopic paraesophageal hernia (PEH) repair has a high hernia recurrence rate. The aim of this study was to assess the 5-year hernia recurrence rate after PEH repair using a combination of bioresorbable mesh and advanced surgical techniques to address tension as needed in a prospective group of patients.
STUDY DESIGN: In 2016, a prospective database was established for 50 patients undergoing primary, elective PEH repair with a new bioresorbable mesh (Phasix ST). Intraoperatively, tension was addressed with Collis gastroplasty and diaphragm relaxing incisions as needed. All 50 patients from the initial study were tracked and asked to return for objective follow-up. Recurrence was considered present for any hernia more than 2 cm in size.
RESULTS: Objective follow-up was conducted in 27 of the original 50 (54%) patients at a median of 5.25 years after their PEH repair. Before the 5-year follow-up, 5 patients had a known recurrent hernia. Objective evaluation at 5 years identified an additional 3 recurrences, for a total recurrence rate of 25% (8 of 32 patients). The hernia recurrence rate in patients with a Collis gastroplasty was significantly lower than in those without a Collis (7% vs 54%, p = 0.008). Two patients underwent reoperation for hernia recurrence. No patient had a mesh infection or mesh erosion.
CONCLUSIONS: The combination of Phasix ST Mesh and tension-reducing techniques during PEH repair led to a 25% hernia recurrence rate at 5 years. The addition of a Collis gastroplasty led to significantly fewer hernia recurrences and is indicative of the potential for esophageal shortening in many patients with a PEH. The long-term safety and efficacy of Phasix ST Mesh in combination with surgical technique for PEH repair is confirmed.
Systems and methods for providing decision making support for surgical procedures are disclosed. A system may include at least one processor configured to implement a method comprising receiving video footage of a surgical procedure performed by a surgeon on a patient in an operating room. The method may comprise accessing at least one data structure including image-related data characterizing surgical procedures. The method may include analyzing received video footage using image-related data to determine an existence of a surgical decision making junction. The method may include accessing, in at least one data structure, a correlation between an outcome and a specific action taken at a decision making junction. Based on a determined existence of a decision making junction and an accessed correlation, the method may include outputting a recommendation to a surgeon to undertake a specific action or to avoid a specific action.
Participants randomly assigned to receive doxazosin (target dose of 16 mg/day). Doxazosin will be initiated at 1 mg/day for the first week, 2mg/day for the second week, 4mg/day for the third week, 8mg/day for the fourth week, and then increase to 16 mg/day for the remaining eight weeks (as tolerated). Research staff administered the study medication at the weekly visits, and participants were given take-home doses of the medication to self-administer on the days in between study visits.
A healthcare system is provided for a care-giving facility. The healthcare system has a medical device, a user interface, a first central computer, and a second central computer. The first central computer has a first database and a first functional feature set associated with the data and functions related to the medical device and the user interface. The medical device and user interface communicate directly with first central computer. The second central computer has a second database and a second functional feature set. The first central computer is securely connected to the second computer, and the medical device and the user interface do not communicate directly with the second central computer. The user interface can receive data from the second database relating to the second functional feature set of the second central computer through the first central computer.
FIELD: medicine.SUBSTANCE: invention relates to the field of medicine, namely to cardiology. Myocardial perfusion is analyzed by volumetric computed tomography (VCT), with pharmacological breakdown of sodium adenosine triphosphate (ATP), which is performed in two stages. At the first stage, the examination is carried out at rest with introduction of a contrast agent. At the second stage - not less than 20 minutes after the first introduction of the contrast preparation, the study is carried out in a stress state which is induced by infusion through a peripheral venous catheter of 1 % ATP solution at rate of 0.10–0.20 mg/kg in minute for 1–5 minutes. At the same time from the beginning of infusion of ATP or when the criteria for stopping the pharmacological test, such as the occurrence of retrosternal pains and/or ischemic ECG dynamics, without interrupting the infusion, 60–90 mg of a non-ionic iodine-containing contrast preparation with concentration of 350–370 mg of iodine/ml is introduced intravenously bolus at rate of 4–5 ml/s. At the same time at the first and second stages prior to the introduction of the contrast preparation, a natural examination is carried out, all stages of the VCT are necessarily performed with prospective synchronization with the ECG in the diastole phase, where the trigger is set for 65–93 % of the cardiac cycle phase. ECG electrodes are applied so that they are outside the field of the projection of the heart with the possibility of excluding artefacts from them in the left ventricular myocardial perfusion assessment zone. At the second stage, additional blood pressure control is performed, and as a result of the VCT, tomographs are taken without artifacts from LV motion, which characterize at least one phase of the cardiac cycle, at least 360 sections. Weakening of the myocardial density (MD) is determined on the basis of which the following values are calculated: a contrast index (CI) as a relation of myocardial infarction on the entire section to an MD of the subendocardial segment with reduced contrast enhancement. That is followed by determining the myocardial perfusion reserve (MPR), which is calculated as the ratio of infrared rest to infrared load. If the MPR value ≤ 0.7 is the presence of left ventricular myocardial ischemia.EFFECT: method enables diagnosing left ventricular myocardial ischemia with varying degrees of coronary artery changes, avoiding multiple-stage examination of patients, more accurate diagnosis verification for the purpose of timely drug-induced intervention and improved patient's prognosis.1 cl, 4 dwg, 3 ex
This patent application is for a new composition of matter called “neuX”. It consists of two or more fundamental particles, called neutrons, that have no electric charge and are bound together by the so-called “strong forces”. Units of neuX, which may consist of any number of neutrons, are for use in the creation of nuclear medicines and for therapeutic treatment to help cure all types of cancer, cancer bone pain, hyperthyroidism, polycythaemia, arthritis, and many other diseases. Units of neuX can also be used in the creation of many hydrogenous compounds, and other chemical compounds that have a variety of medical and industrial applications. NeuX units are formed of neutrons obtained from nuclear reactors, and also by many different nuclear reactions including the bombardment of certain elements, such as beryllium, with alpha particles from radioactive sources. Neutrons can be released by the irradiation of deuterium with high-energy gamma rays. It is well known that free neutrons are radioactive with a half-life of about fifteen minutes. However, in a strongly bound state, such as in a neuX unit or the deuteron, which consists of a neutron and a proton, there is no radioactivity.
* Burden: Watery diarrhea including cholera continues to be a major cause of childhood mortality in developing countries, with an estimated 1.5 million children dying each year. This figure has greatly reduced from approximately 5 million diarrheal deaths annually 20 years ago, a phenomenon often attributed to the utilization of oral rehydration solution (ORS).
* Knowledge Gap: ORS is very effective in correcting dehydration and reducing mortality, but is not adequately used in many countries, partly due to the fact that it does not reduce diarrhea. The physiological basis for ORS is that glucose-stimulated sodium and fluid absorption is not inhibited by cyclic 3',5'-adenosine monophosphate (cAMP) and other diarrhea mediators which inhibit sodium chloride absorption. The conventional glucose-based ORS does not reduce duration or severity of diarrhea and may in fact paradoxically increase fecal fluid losses. Advances in ORS composition have included the universal adoption of hypo-osmolar ORS (HO-ORS) in 2003. Recent technological innovations have led to the use of amylase-resistant starches and their modifications in the treatment of diarrhea. Short chain fatty acids (SCFA), which are produced in colon from these non-absorbed carbohydrates, enhance sodium absorption. An orally administered, non-absorbed starch (i.e., one resistant to digestion by amylase) significantly reduced fecal fluid loss and the duration of diarrhea in patients with cholera.
* Relevance: Efforts are continuing to improve the efficacy of oral rehydration solution. As glucose stimulates sodium and water absorption in small intestine, short chain fatty acids (SCFAs) stimulate sodium and water absorption in the colon. In cholera, colonic function is also impaired due to the lack of SCFAs. The main source of SCFAs is the unabsorbed carbohydrates that are fermented in the colon by the colonic bacteria. The maize starch contains substantial amount of amylase resistant starch that escapes digestion and absorption in the small intestine and is fermented in the colon, liberating SCFAs. We expect that our experimental ORS containing maize starch will reduce the severity (stool volume) and enhance recovery (reduce duration) of diarrhoea.
BACKGROUND: Mental disorders such as depression, anxiety and stress are becoming more common worldwide. The aim of this study was to examine the relationship between dietary inflammations scores (DIS) and lifestyle inflammation scores (LIS) and the risk of depression, stress, and anxiety in a large sample of Iranian adults.
METHODS: This study was based on 5579 adults (20-70 years) who participated in the Yazd Health Study (YaHS). The DIS score was calculated from the intake of 19 food groups and the LIS score was derived from four components. Multivariable logistic regression models were used to estimate the odds ratio (ORs) and 95 % confidence interval (CI) of depression, stress, and anxiety across quartiles of DIS and LIS.
RESULTS: 2749 of the participants (46 % male) had anxiety, depression and stress. According to the adjusted model, there was a positive association between LIS and the risk of anxiety (OR: 1.23, 95 % CI: 1.01-1.49) and depression (OR: 1.39, 95 % CI: 1.14-1.69, P for trend: 0.03). However, there was no significant association between LIS and the risk of stress. There was also no significant association between DIS and the risk of anxiety, depression and stress.
CONCLUSIONS: This study demonstrated that higher LIS scores were associated with depression and anxiety. It is suggested that following a LIS that includes smoking status, physical activity, alcohol consumption, and body mass index as indicators of the inflammatory promoting lifestyle, may increase the risk of depression and anxiety.
Dose level: 10mg/day, 20mg/day, 40mg/day, 60mg/day, 80mg/day, 100mg/day. Each dose level will recruit 3-6 subjects, taking ETH-155008 tablets once daily.
Cancer survivors assigned to this condition continued with the standard follow-up care provided by their treating oncologists as appropriate for individual diagnoses. Participants in the control condition were offered the 4-week YOCAS©® program gratis after completing all study requirements.
PURPOSE:To obtain a cosmetic effective in preventing and remedying skin cornification, skin chap, rush, etc., by compounding an extracted liquid of the leaf of Corchorus olitorius. CONSTITUTION:Raw or dried leaf of Corchorus olitorius which is a green vegetable having high nutrient value is extracted and the obtained liquid is compounded to a cosmetic base to obtain the objective cosmetic. The extraction is carried out by adding 1-50 pts. of an extraction solvent to 1 pt. of Corchorus olitorius leaves, thoroughly grinding the mixture in a mortar and extracting under stirring or by using a Soxhlet extractor. The extraction solvent is preferably purified water. The viscosity of the extraction object sometimes increases to make the extraction difficult owing to viscous substance existing in Corchorus olitorius. The trouble can be eliminated by using 5-100% of an alcohol such as ethanol.
PROBLEM TO BE SOLVED: To enable rapid recovery of the moistening components for skin which has been lost by washing by massaging before the application of a skin care cosmetic after skin washing. SOLUTION: Skin is washed by cleansing and washing and skin-care cosmetics are applied. At this time, a massage cosmetic containing disintegrative particles is used to effect massage after the skin cleansing and before washing with a washing agent. Or after washing with a skin-washing agent, and before application of cosmetic, the massage cosmetic containing disintegrative particles is used to effect massage. As the skin care cosmetic, at first a skin lotion is used, then a milk lotion or cream is applied. The massage cosmetic contains disintegrative granules or disintegrative microcapsules. Thus, effective skin care can be conveniently performed in combination with massage even in the case of usual persons.
Conventional treatment plus NK cells. Participants will receive conventional treatment plus twice a week of NK cells (0.1-2\*10E7 NK cells/kg body weight).
PURPOSE:To provide a new compound useful as a reagent for chemical modification of a gene, capable of readily detecting point mutation of a gene in hereditary diseases and applicable to, e.g. diagnosis of a hereditary disease. CONSTITUTION:There us provided a compound of formula I (R<1> is a 1 to 6C alkyl or a cycloalkyl; R<2> is a 1 to 6C alkylene; R<3> and R<4> are each a 1 to 3C alkyl; X is a halogen ion), e.g. 1-cyclohexyl-3-{[biotinylhydrazinoxomethyl)- dimethylammono]propyl}carbodiimide bromide. This compound can be obtained in the form of a white precipitate, e.g. by reacting a compound of formula II with a compound of formula III in a polar solvent and subsequently adding the resultant reaction mixture to ether. In addition, the above reaction is carried out generally at 10 to 60 deg.C preferably by using the compound of formula II and the compound of formula III in a molar ratio of 1:1. As the polar solvent, DMF, etc., is preferably used.
The target sample of this study will be approximately 200 primary care physician-patient consultations who discuss CRC screening during the course of a clinical visit. Physician and patient participants will come from primary care practices associated with the New York City Research and Improvement Networking Group (NYC RING).